External broker reports(aggregated public sources), Axis Direct

Axis Direct

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Profitability Impacted by Headwinds: Reported revenue grew 8.1% YoY to Rs 602 Cr, in line with estimates.</li><li>However, operational profits missed expectations as lower utilisation levels and temporary shutdowns compressed margins to a multi-quarter low of 9.1%.</li><li>Management, however, guides to a volume-led recovery from Jan’26, driven by backward integration and ramp-up of new facilities</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Profitability Impacted by Headwinds: Reported revenue grew 8.1% YoY to Rs 602 Cr, in line with estimates.However, operational profits missed expectations as lower utilisation levels and temporary shutdowns compressed margins to a multi-quarter low of 9.1%.Management, however, guides to a volume-led recovery from Jan’26, driven by backward integration and ramp-up of new facilitiesContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Aarti Drugs Ltd - Operational Headwinds Cloud Q3FY26

<ul><li>Uptick in Revenue and Profitability: Revenue, EBITDA, and Adjusted PAT increased by 9.1%, 25.7%, and 29.2% YoY, respectively, driven by strong demand in API, especially in the export market, leading to overall volume growth of 9% and negative variance of ~2%.</li><li>Encouraging Segment-wise Performance: The Formulations business saw a significant jump of 25% annually, while the API reported muted growth of 6.4%.</li><li>The company is now focused on expanding into more international markets. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Uptick in Revenue and Profitability: Revenue, EBITDA, and Adjusted PAT increased by 9.1%, 25.7%, and 29.2% YoY, respectively, driven by strong demand in API, especially in the export market, leading to overall volume growth of 9% and negative variance of ~2%.Encouraging Segment-wise Performance: The Formulations business saw a significant jump of 25% annually, while the API reported muted growth of 6.4%.The company is now focused on expanding into more international markets. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance

<ul><li>Aarti Drugs reported revenue of Rs 591 Cr, marginally below our estimate of Rs 598 Cr, yet broadly in line with expectations.</li><li>Revenue grew by 6.3% YoY, supported by a recovery in demand and volume growth, particularly in the API segment.</li><li>EBITDA stood at Rs 74 Cr, exceeding our estimate of Rs 69 Cr, registering a 13.9% YoY increase. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Aarti Drugs reported revenue of Rs 591 Cr, marginally below our estimate of Rs 598 Cr, yet broadly in line with expectations.Revenue grew by 6.3% YoY, supported by a recovery in demand and volume growth, particularly in the API segment.EBITDA stood at Rs 74 Cr, exceeding our estimate of Rs 69 Cr, registering a 13.9% YoY increase. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Aarti Drugs Ltd - Margin Gains & Expansion Plans Fuel Optimism for H2

Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Market & Forensics Analyst

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Thematic (Sector/Industry)

<ul>
<li>Several companies across industries have commissioned capacity expansions. These completions reflect management's strong demand outlook and are often precursors to improved financial performance and long-term value creation.</li>
<li>The completion of strategic Capex enhances revenue streams and EBITDA margins, positioning companies for sustainable growth, improved financial performance, and greater investor confidence amid evolving market demands.</li>
<li>Tracking newly completed capacities helps identify companies entering growth mode. As utilization improves and integration lowers costs, earnings visibility strengthens, supporting upgraded forecasts and potential valuation upside.</li>
</ul>


Several companies across industries have commissioned capacity expansions. These completions reflect management's strong demand outlook and are often precursors to improved financial performance and long-term value creation.
The completion of strategic Capex enhances revenue streams and EBITDA margins, positioning companies for sustainable growth, improved financial performance, and greater investor confidence amid evolving market demands.
Tracking newly completed capacities helps identify companies entering growth mode. As utilization improves and integration lowers costs, earnings visibility strengthens, supporting upgraded forecasts and potential valuation upside.


Capex Monetization: Revenue Impact, Margin Expansion Across Companies

<ul><li>Post Budget Analysis and Stock Ideas: It gives us immense joy to announce our Post Budget Analysis and Stock Ideas for 2024-25.</li><li>The report contains carefully handpicked companies that are well-placed to benefit from this year’s Interim Budget.</li><li>NEW YEAR PICKS 2024: In Dec’23, we released the report – NEW YEAR PICKS 2024: New Year, New Horizons, which contains deeplyresearched 9 stocks that are best-placed to deliver excellent performance in 2024. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Post Budget Analysis and Stock Ideas: It gives us immense joy to announce our Post Budget Analysis and Stock Ideas for 2024-25.The report contains carefully handpicked companies that are well-placed to benefit from this year’s Interim Budget.NEW YEAR PICKS 2024: In Dec’23, we released the report – NEW YEAR PICKS 2024: New Year, New Horizons, which contains deeplyresearched 9 stocks that are best-placed to deliver excellent performance in 2024. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Axis Research Scorecard Report for Jan 2024

India

Aarti Drugs Limited is a pharmaceutical company which manufactures bulk drugs and specialty chemicals. The Company's products include vitamins and sedatives, as well as anti-inflammatory, anti-asthma, anti-arthritis, anti-fungal,  anti-diabetic, anti-osteoporosis, anti-cholinergic and anti-depressant drugs.  The company sells its products in India and elsewhere throughout the world.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Aarti Drugs Ltd (ARTD IN)

Aarti Drugs Ltd - Operational Headwinds Cloud Q3FY26

Management, however, guides to a volume-led recovery from Jan’26, driven by backward integration and ramp-up of new facilities

Axis Direct

Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance

Encouraging Segment-wise Performance: The Formulations business saw a significant jump of 25% annually, while the API reported muted growth of 6.4%.

Axis Direct

Aarti Drugs Ltd - Margin Gains & Expansion Plans Fuel Optimism for H2

Aarti Drugs reported revenue of Rs 591 Cr, marginally below our estimate of Rs 598 Cr, yet broadly in line with expectations. Revenue grew by 6.3%...

Axis Direct

Capex Monetization: Revenue Impact, Margin Expansion Across Companies

Companies are expanding capacity to meet strong demand, improve financial performance, and create long-term value, positioning them for...

Nimish Maheshwari

Axis Research Scorecard Report for Jan 2024

Post Budget Analysis and Stock Ideas: It gives us immense joy to announce our Post Budget Analysis and Stock Ideas for 2024-25.

Axis Direct

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Aarti Drugs Ltd - Operational Headwinds Cloud Q3FY26

Management, however, guides to a volume-led recovery from Jan’26, driven by backward integration and ramp-up of new facilities

Axis Direct

Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance

Encouraging Segment-wise Performance: The Formulations business saw a significant jump of 25% annually, while the API reported muted growth of 6.4%.

Axis Direct

Aarti Drugs Ltd - Margin Gains & Expansion Plans Fuel Optimism for H2

Aarti Drugs reported revenue of Rs 591 Cr, marginally below our estimate of Rs 598 Cr, yet broadly in line with expectations. Revenue grew by 6.3%...

Axis Direct

Capex Monetization: Revenue Impact, Margin Expansion Across Companies

​Companies are expanding capacity to meet strong demand, improve financial performance, and create long-term value, positioning them for...

Nimish Maheshwari

Axis Research Scorecard Report for Jan 2024

Post Budget Analysis and Stock Ideas: It gives us immense joy to announce our Post Budget Analysis and Stock Ideas for 2024-25.

Axis Direct

Companies are expanding capacity to meet strong demand, improve financial performance, and create long-term value, positioning them for...